检索结果-南通市图书馆

Modelling the prevalence of hepatitis C virus amongst blood donors in Libya:An investigation of providing a preventive strategy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Virology 2016年第1期5卷 14-22页

作者： Mohamed A Daw Amira Shabash Abdallah El-Bouzedi Aghnya A Dau Moktar Habas Libyan study group of hepatitis and HIV Acting Physician of Internal Medicine Scientific Coordinator of Libyan National Surveillance Studies of Viral hepatitis and HIVTripoli 82668Libya Department of Medical Microbiology Faculty of MedicineTripoli 82668Libya Department of Laboratory Medicine Faculty of BiotechnologyTripoli 82668Libya Department of Surgery Faculty of MedicineTripoli Medical CenterTripoli 82668Libya Department of Medicine Faculty of MedicineTripoli Central HospitalTripoli 82668Libya 不详

AIM: To determine hepatitis C virus(HCV) seroprevalence among the Libyan population using blood donors and applying the autoregressive integrated moving average(ARIMA) model to predict future trends and formulate plans to minimize the burden of HCV ***: HCV positive cases were collected from 1008214 healthy blood donors over a 6-year period from 2008 to 2013. Data were used to construct the ARIMA model to forecast HCV seroprevalence among blood donors. The validity of the model was assessed using the mean absolute percentage error between the observed and fitted seroprevalence. The fitted ARIMA model was used to forecast the incidence of HCV beyond the observed period for the year 2014 and further to ***: The overall prevalence of HCV among blood donors was 1.8%, varying over the study period from 1.7% to 2.5%, though no significant variation was found within each calendar year. The ARIMA model showed a non-significant auto-correlation of the residuals, and the prevalence was steady within the last 3 years as expressed by the goodness-of-fit test. The forecast incidence showed an increase in HCV seropositivity in 2014, ranging from 500 to 700 per 10000 population, with an overall prevalence of 2.3%-2.7%. This may be extended to 2055 with minimal periodical variation within each 6-year ***: The applied model was found to be valuable in evaluating the seroprevalence of HCV among blood donors, and highlighted the growing burden of such infection on the Libyan health care system. The model may help in formulating national policies to prevent increases in HCV infection and plan future strategies that target the consequences of the infection.

关键词： Autoregressive integrated moving average model Libya hepatitis C virus Blood donors

天晴复欣针剂、胶囊序贯治疗慢性乙型肝炎多中心疗效观察

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华实验和临床病毒学杂志 2006年第4期20卷 396-398页

作者：张馨许家璋张玲霞南京第八十一医院肝病研究所南京210002

目的评价天晴复欣针剂、胶囊序贯治疗慢性乙型肝炎的疗效和安全性。方法174例选自各中心按统一标准入组的患者均采用天晴复欣注射剂与胶囊序贯治疗6个月,停药随访6个月。监测肝功能(ALT、AST、TBil)及HBV-M、HBVDNA。结果治疗6个月后患... 详细信息

目的评价天晴复欣针剂、胶囊序贯治疗慢性乙型肝炎的疗效和安全性。方法174例选自各中心按统一标准入组的患者均采用天晴复欣注射剂与胶囊序贯治疗6个月,停药随访6个月。监测肝功能(ALT、AST、TBil)及HBV-M、HBVDNA。结果治疗6个月后患者的ALT、AST复常率分别为54.23%、56.91%,TBil的复常为54.17%;停药随访6个月分别为69.91%、61.22%和80.56%。天晴复欣治疗3个月、6个月时HBeAg阴转率分别为22.58%、36.94%,其中发生HBeAg/HBeAb转换分别为12.90%、17.12%;治疗3个月、6个月后HBVDNA下降≥2log10分别为20.12%、28.17%。治疗3个月、6个月后完全应答率分别为3.05%、5.63%,部分应答率为19.51%、35.21%。停药后随访6个月时5.31%的患者仍可维持完全应答疗效。结论天晴复欣有一定的抗病毒作用,且随治疗时间的延长其疗效增高。

关键词：天晴复欣治疗结果肝炎,乙型,慢性

Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2011年第45期17卷 4987-4992页

作者： Orhan Yιldιz Bilgehan Aygen Nese Demirtürk Tuna Demirdal Dilara Inan Taner Yιldιrmak Arzu Kantürk Ediz Tütüncü hepatitis B study group Department of Infectious Diseases and Clinical Microbiology Medical School of Erciyes University Department of Infectious Diseases and Clinical Microbiology Medical School of Kocatepe University Department of Infectious Diseases and Clinical Microbiology Medical School of Akdeniz University Okmeydani Training and Research Hospital of the Ministry of Health 34384 Istanbul Turkey SB Diskapi Yildirim Beyazit Training and Research Hospital of the Ministry of Health

AIM: To determine the distribution of viral genotypes for primary or acquired lamivudine resistance. METHODS: A total of 283 patients with chronic hepatitis B virus (HBV) infection (245 patients with chronic hepatitis B and 38 inactive hepatitis B surface antigen carriers) were included in the study. The HBV geno-type was determined by using quantitative real-time polymerase chain reaction and sequence analysis, and tyrosine-methionine-aspartate-aspartate (YMDD) motif mutations were determined using the reverse transcriptase hybridization method. RESULTS: Lamivudine resistance was determined in a total of 25 (10.7%) chronic hepatitis B patients. Eight subjects (4%) had primary resistance to lamivudine, and 17 (53.1%) had secondary resistance to lamivudine. Genotype D, which was isolated from 267 of the patients with chronic HBV infection, was the dominant genotype in Turkey. CONCLUSION: Identification of YMDD motif mutations should have a positive impact on the selection of proper antiviral medication for patients, even for those who are nucleoside nave.

关键词： hepatitis B virus Genotype Resistance Lamivudine Tyrosine-methionine-aspartate-aspartate mutation

Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2021 Edition)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2022年第3期2卷 145-167页

作者： AIDS and hepatitis C Professional group,Society of Infectious Diseases,Chinese Medical Association Chinese Center for Disease Control and Prevention Taisheng Li 不详

Acquired immunodeficiency syndrome(AIDS)is an important public health problem in *** 2005,the first edition of the guidelines for the diagnosis and treatment of AIDS was formulated by the AIDS Professional group of Society of Infectious Diseases of Chinese Medical Association,which was updated in 2011,2015,and 2018,*** 2021 edition of the guidelines has been revised based on the fourth edition and updated according to the national clinical practice and the latest research findings on opportunistic infections,antiretro viral therapy,post-exposure prophylaxis,pre-exposure prophylaxis(PrEP),whole-course management of human immunodeficiency virus infections,and prevention of mother to child *** 2021 edition also introduces in detail the indications,medication regimen,follow-up and monitoring,and precautions for *** guide will be updated regularly according to the latest clinical evidence.

关键词： Acquired immunodeficiency syndrome Diagnosis Guideline HIV Treatment

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

甲型病毒性肝炎暴发调查指南(2021版)

中华预防医学杂志 2022年第5期56卷 549-553页

作者：《甲型病毒性肝炎暴发调查指南》编写组陈园生张丽杰毕胜利不详中国疾病预防控制中心科技处北京102206 中国疾病预防控制中心教育培训处北京100050 中国疾病预防控制中心病毒病预防控制所北京102206

我国甲型肝炎报告发病率从1991年的56/10万下降到2020年的1.05/10万,甲型肝炎暴发数量较以前明显减少,但近5年也时有报道,仍存在风险。为加强对全国甲型肝炎暴发疫情调查处置和预防控制工作的技术指导,中国疾病预防控制中心组织相关领... 详细信息

我国甲型肝炎报告发病率从1991年的56/10万下降到2020年的1.05/10万,甲型肝炎暴发数量较以前明显减少,但近5年也时有报道,仍存在风险。为加强对全国甲型肝炎暴发疫情调查处置和预防控制工作的技术指导,中国疾病预防控制中心组织相关领域专家,联合编写了本指南。本指南包括甲型肝炎暴发的监测和定义,甲型肝炎疫情的识别和报告,暴发疫情的规范调查和处置原则、调查结果的交流与反馈等。本指南适用于各级卫生行政部门、医疗保健机构、疾病预防控制机构、卫生监督机构以及相关集体、单位和个人。中国疾病预防控制中心将根据指南执行过程中反馈的问题和学科进展定期对指南进行修订。

关键词：肝炎,甲型疾病暴发流行调查处置指南

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic hepatitis B Patients

在线全文

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第3期11卷 649-660页

作者： Zhihong Liu Qinglong Jin Yuexin Zhang Guozhong Gong Guicheng Wu Lvfeng Yao Xiaofeng Wen Zhiliang Gao Yan Huang Daokun Yang Enqiang Chen Qing Mao Shide Lin Jia Shang Huanyu Gong Lihua Zhong Huafa Yin Fengmei Wang Peng Hu Qiong Wu Chao Pan Wen Jia Chuan Li Chang’an Sun Junqi Niu Jinlin Hou TMF study group Department of Infectious Diseases and Hepatology Unit Institutes of Liver Diseases Research of Guangdong ProvinceNan-fang HospitalSouthern Medical UniversityGuangzhouGuangdongChina The First Hospital of Jilin University Chang-chunJilinChina The First Affiliated Hospital of Xinjiang Medical University UrumqiXinjiangChina The Second Xiangya Hospital of Central South University ChangshaHunanChina Chongqing University Three Gorges Hospital ChongqingChina Mengchao Hepatobiliary Hospital of Fujian Medical University FuzhouFujianChina Liuzhou People’s Hospital LiuzhouGuangxiChina The Third Affiliated Hospital of Zhongshan University GuangzhouGuangdongChina Xiangya Hospital of Central South University ChangshaHunanChina The First Affiliated Hospital of Xinxiang Medical University XinxiangHenanChina West China Hospital of Sichuan University ChengduSichuanChina The Southwest Hospi-tal of AMU ChongqingChina Affiliated Hospital of Zunyi Medical University ZunyiGuizhouChina Henan Provincial People’s Hospital ZhengzhouHenanChina The Third Xiangya Hospital of Central South University ChangshaHunanChina The Fourth Affiliated Hospital of Harbin Medical University HarbinHeilongjiangChina The First Affiliated Hospi-tal of Anhui Medical University HefeiAnhuiChina Tianjin Third Central Hospital TianjinChina The Second Affiliated Hospital of Chongqing Medical University ChongqingChina Jiangsu Hansoh Pharmaceutical group Co. LtdLianyungangJiangsuChina Members listed in the Supplementary File 1

Background and Aims:Tenofovir amibufenamide(TMF)is a novel phosphoramidated prodrug of tenofovir with nonin-ferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate(TDF)in 48 weeks of ***,we update 96-week comparison ***:Patients with chronic hepatitis B were assigned(2:1)to receive either 25 mg TMF or 300 mg TDF with matching placebo for 96 *** virological suppression was defined as HBV DNA levelsgroup in both HBeAg-positive and HBeAg-negative *** efficacy was maintained in the pooled population,while it was first achieved in patients with HBV DNA≥7 or 8 log10 IU/mL at ***-indexed estimated glomerular filtration rate for renal safety assessment was adopted,while a smaller decline of which was seen in the TMF group than in the TDF group(p=0.01).For bone mineral density,patients receiv-ing TMF displayed significantly lower reduction levels in the densities of spine,hip,and femur neck at week 96 than those receiving *** addition,the lipid parameters were stable after week 48 in all groups while weight change still showed the opposite ***:TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles(NCT03903796).

关键词： hepatitis B Liver function tests viral hepatitis Liver Osteoporosis

人肝再生增强因子对人外周血单个核细胞增殖的影响及其机制

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国生物制品学杂志 2009年第10期22卷 961-963页

作者：王新国刘杞孙航梁珊谢松丽张宏华重庆医科大学病毒性肝炎研究所教育部感染性疾病分子生物学重点实验室重庆400010

目的探讨人肝再生增强因子(hALR)对人外周血单个核细胞(PBMC)增殖的影响及其机制。方法梯度离心分离PBMC,将细胞分为正常对照组、刀豆蛋白A(ConA)(5mg/L)组和ConA(5mg/L)+hALR(30mg/L)组,分别培养10min、30min、1h、2h、4h后,MTT法检测... 详细信息

目的探讨人肝再生增强因子(hALR)对人外周血单个核细胞(PBMC)增殖的影响及其机制。方法梯度离心分离PBMC,将细胞分为正常对照组、刀豆蛋白A(ConA)(5mg/L)组和ConA(5mg/L)+hALR(30mg/L)组,分别培养10min、30min、1h、2h、4h后,MTT法检测各组各时间点细胞增殖水平,钙荧光指示剂法检测细胞内游离Ca2+浓度的变化,Western blot法检测细胞内胞外信号调节激酶(ERK)的磷酸化程度。结果4h内,各组细胞的增殖水平差异无统计学意义,但ConA组细胞增殖水平已表现出逐渐升高的趋势。正常对照组细胞内Ca2+浓度在加入Fluo-3/AM后2h达高峰,ConA组1h达高峰,ConA+hALR组10min达高峰。正常对照组细胞内磷酸化的ERK随培养时间的延长而逐渐减少;ConA组细胞内磷酸化的ERK在30min达高峰,之后逐渐降低;ConA+hALR组细胞内磷酸化的ERK在2h前明显低于ConA组。结论hALR可能通过影响细胞内Ca2+浓度的变化峰值和磷酸化的ERK,来抑制人PBMC的免疫功能,从而影响其增殖。

关键词：人肝再生增强因子外周血单个核细胞细胞增殖钙离子胞外信号调节激酶

ALT持续正常的慢性HBV感染者诊疗专家共识

在线全文

学校读者我要写书评

暂无评论

临床肝胆病杂志 2021年第10期37卷 2286-2291页

作者：中国研究型医院学会肝病学分会病毒性肝炎学组陈永平杨永平丁惠国林明华张明香陈良邓存良邬小萍李用国林锋不详温州医科大学附属第一医院肝病中心中国人民解放军总医院第五医学中心肝病医学部首都医科大学附属北京佑安医院肝病消化中心福建医科大学孟超肝胆医院感染科沈阳市第九人民医院肝病科上海市公共卫生临床中心肝病科西南医科大学附属医院感染科南昌大学第一医院感染科重庆医科大学附属第一医院感染科海南省人民医院感染科

本共识基于我国《慢性乙型肝炎防治指南(2019版)》[1],对ALT持续正常的慢性乙型肝炎的最新进展进行补充,旨在帮助临床医师在ALT持续正常慢性乙型肝炎患者的诊治中做出合理的诊疗决策。本共识中的证据分为A、B和C 3个等级,推荐等级分为1... 详细信息

本共识基于我国《慢性乙型肝炎防治指南(2019版)》[1],对ALT持续正常的慢性乙型肝炎的最新进展进行补充,旨在帮助临床医师在ALT持续正常慢性乙型肝炎患者的诊治中做出合理的诊疗决策。本共识中的证据分为A、B和C 3个等级,推荐等级分为1和2级(表1)。

关键词：乙型肝炎,慢性丙氨酸转氨酶共识

重型病毒性肝炎治疗研究(附121例疗效与预后分析)

在线全文

学校读者我要写书评

暂无评论

中华传染病杂志 1988年第2期6卷 81-84页

作者：全国重症肝炎攻关协作组

1983年10月～1985年10月对121例经病理确诊的急性和亚急性重型肝炎,应用免疫调控、抗肝细胞坏死、抗肝昏迷、抗出血、抗感染及抗病毒的综合疗法,结果死亡66例,病死率为54.54%,且死亡病例的平均存活时间较传统疗法明显延长(49.67±39.85... 详细信息

1983年10月～1985年10月对121例经病理确诊的急性和亚急性重型肝炎,应用免疫调控、抗肝细胞坏死、抗肝昏迷、抗出血、抗感染及抗病毒的综合疗法,结果死亡66例,病死率为54.54%,且死亡病例的平均存活时间较传统疗法明显延长(49.67±39.85天比18.5±16.51天,P＜O.05).由于昏迷与出血得到较好的控制,肝肾综合征跃居死亡原因的首位.血清胆红素浓度、凝血酶原活性、肝昏迷级别、激素应用与否与预后有一定的关系,而性别、年龄、病原、起病急缓、腹水有无与预后关系不大.

关键词：重型病毒性肝炎联合疗法病死率较低